


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 231/54, 261/20, 239/70, 471/04, 495/04, 405/12, A61K 31/42, 31/415, 31/505</p>	<p>A1</p>	<p>(11) International Publication Number: WO 95/07893 (43) International Publication Date: 23 March 1995 (23.03.95)</p>
<p>(21) International Application Number: PCT/GB94/01936 (22) International Filing Date: 6 September 1994 (06.09.94) (30) Priority Data: 9319110.4 15 September 1993 (15.09.93) GB 9319151.8 16 September 1993 (16.09.93) GB (71) Applicant (for all designated States except US): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): DAVEY, William, Barn- aby [GB/GB]; Terlings Park, Eastwick Road, Harlow, Es- sex CM20 2QR (GB). LEESON, Paul, David [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). ROWLEY, Michael [GB/GB]; Terlings Park, East- wick Road, Harlow, Essex CM20 2QR (GB). (74) Agent: HISCOCK, Ian, James; Merck & Co., Inc., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).</p>		<p>(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.</p>
<p>(54) Title: FUSED TRICYCLIC HETEROAROMATIC DERIVATIVES AS DOPAMINE RECEPTOR SUBTYPE LIGANDS</p> <p>(57) Abstract</p> <p>A class of fused tricyclic heteroaromatic compounds of formula (I), or a salt thereof or a prodrug thereof, containing a fused pyrazole, oxazole or pyrimidine ring are ligands for dopamine receptor subtypes within the body and are therefore of use in the treatment and/or prevention of disorders of the dopamine system, such as schizophrenia.</p> <div style="text-align: right;">  <p>(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

FUSED TRICYCLIC HETEROAROMATIC DERIVATIVES AS DOPAMINE RECEPTOR SUBTYPE
LIGANDS

5 This invention relates to a particular class of
fused tricyclic heteroaromatic compounds based on a
substituted isoxazole or pyrazole moiety. These
compounds are ligands for dopamine receptor subtypes
within the body and are therefore of use in the treatment
and/or prevention of disorders of the dopamine system,
10 including schizophrenia, depression, nausea, Parkinson's
disease, tardive dyskinesias and extrapyramidal side-
effects associated with treatment by conventional
neuroleptic agents, neuroleptic malignant syndrome, and
disorders of hypothalamic-pituitary function such as
15 hyperprolactinaemia and amenorrhoea.

Upper gastrointestinal tract motility is
believed to be under the control of the dopamine system.
The compounds according to the present invention may thus
be of use in the prevention and/or treatment of
20 gastrointestinal disorders, and the facilitation of
gastric emptying.

Dependence-inducing agents such as cocaine and
amphetamine have been shown to interact with the dopamine
system. Compounds capable of counteracting this effect,
25 including the compounds in accordance with the present
invention, may accordingly be of value in the prevention
or reduction of dependence on a dependence-inducing
agent.

Dopamine is known to be a peripheral
30 vasodilator; for example, it has been shown to exert a
dilatory effect on the renal vascular bed. This implies
that the compounds of the present invention may be
beneficial in controlling vascular blood flow.

The localisation of dopamine receptor mRNA in
35 rat heart and large vessels has been noted. This
suggests a role for dopamine receptor ligands in


- 2 -

controlling cardiovascular function, either by affecting cardiac and smooth muscle contractility or by modulating the secretion of vasoactive substances. The compounds according to the present invention may therefore be of assistance in the prevention and/or treatment of such conditions as hypertension and congestive heart failure.

Molecular biological techniques have revealed the existence of several subtypes of the dopamine receptor. The dopamine D₁ receptor subtype has been shown to occur in at least two discrete forms. Two forms of the D₂ receptor subtype, and at least one form of the D₃ receptor subtype, have also been discovered. More recently, the D₄ (Van Tol *et al.*, *Nature* (London), 1991, 350, 610) and D₅ (Sunahara *et al.*, *Nature* (London), 1991, 350, 614) receptor subtypes have been described.

The compounds in accordance with the present invention, being ligands for dopamine receptor subtypes within the body, are accordingly of use in the treatment and/or prevention of disorders of the dopamine system.

The present invention accordingly provides a compound of formula I, or a salt thereof or a prodrug thereof:



wherein the broken line represents a double bond whereby the heteroaromatic ring containing Q is aromatic;

- 3 -

W represents the residue of an optionally substituted aromatic or heteroaromatic ring;

Q represents the residue of a heteroaromatic ring selected from $=N-NR^5-$, $-NR^5-N=$, $=N-O-$, $-O-N=$ and $=N-CR^6=N-$;

Z represents a chemical bond, an oxygen or sulphur atom, or a methylene or ethylene group;

R^1 , R^2 and R^5 independently represent hydrogen or C_{1-6} alkyl;

one of R^3 and R^4 represents hydrocarbon or a heterocyclic group, and the other of R^3 and R^4 represents hydrogen, hydrocarbon or a heterocyclic group; and

R^6 represents C_{1-6} alkyl or $-NR^aR^b$, in which R^a and R^b independently represent hydrogen or C_{1-6} alkyl.

The compounds of the present invention are preferably prepared and utilised in the form of the free base or as a pharmaceutically acceptable salt thereof.

For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts.


Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.

Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

- 4 -

For the avoidance of doubt, it will be appreciated that the present invention relates to compounds of formula (IA), and salts and prodrugs thereof:

5



wherein the broken circle represents two non-adjacent double bonds whereby the five-membered ring containing X and Y is aromatic;

20 W represents the residue of an optionally substituted aromatic or heteroaromatic ring;

one of X and Y represents nitrogen, and the other of X and Y represents oxygen or N-R⁵;

Z represents a chemical bond, an oxygen or sulphur atom, or a methylene or ethylene group;


25 R¹, R² and R⁵ independently represent hydrogen or C₁₋₆ alkyl; and

one of R³ and R⁴ represents hydrocarbon or a heterocyclic group, and the other of R³ and R⁴ represents hydrogen, hydrocarbon or a heterocyclic group.

30 The present invention also relates to compounds of formula (IB), and salts and prodrugs thereof:

35

- 5 -



(1B)

wherein

W represents the residue of an optionally substituted aromatic or heteroaromatic ring;

15 Z represents a chemical bond, an oxygen or sulphur atom, or a methylene or ethylene group;

R¹ and R² independently represent hydrogen or C₁₋₆ alkyl;

20 one of R³ and R⁴ represents hydrocarbon or a heterocyclic group, and the other of R³ and R⁴ represents hydrogen, hydrocarbon or a heterocyclic group; and

R⁶ represents C₁₋₆ alkyl or -NR^aR^b, in which R^a and R^b independently represent hydrogen or C₁₋₆ alkyl.

25 The term "hydrocarbon" as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl, aryl and aryl(C₁₋₆)alkyl.

30 The expression "a heterocyclic group" as used herein includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur. The heterocyclic group suitably contains up to 15 carbon atoms and 35 conveniently up to 12 carbon atoms, and is preferably

- 6 -

linked through carbon. Examples of suitable heterocyclic groups include C₃₋₇ heterocycloalkyl, C₃₋₇ heterocycloalkyl(C₁₋₆)alkyl, heteroaryl and heteroaryl(C₁₋₆)alkyl groups.

5 Suitable alkyl groups include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl and butyl groups. Particular alkyl groups are methyl, ethyl,
10 isopropyl and t-butyl.

 Suitable alkenyl groups include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl and allyl groups.

15 Suitable alkynyl groups include straight-chained and branched alkynyl groups containing from 2 to 6 carbon atoms. Typical examples include ethynyl and propargyl groups.

 Suitable cycloalkyl groups include groups
20 containing from 3 to 7 carbon atoms. Particular cycloalkyl groups are cyclopropyl and cyclohexyl.

 Particular aryl groups include phenyl and naphthyl.

 Particular aryl(C₁₋₆)alkyl groups include
25 benzyl, naphthylmethyl, phenethyl and phenylpropyl.

 Suitable heterocycloalkyl groups include azetidiny, pyrrolidyl, piperidyl, piperazinyl and morpholinyl groups.

 Suitable heteroaryl groups include pyridyl,
30 quinolyl, isoquinolyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, indolyl, aza-indolyl, imidazolyl, oxadiazolyl and thiadiazolyl groups.

 Particular heteroaryl(C₁₋₆)alkyl groups include
35 pyridylmethyl, pyrazinylmethyl, indolylmethyl and aza-indolylmethyl.

- 7 -

The hydrocarbon and heterocyclic groups may in turn be optionally substituted by one or more groups selected from C₁₋₆ alkyl, adamantyl, phenyl, aryl(C₁₋₆)alkyl, halogen, C₁₋₆ haloalkyl, C₁₋₆ aminoalkyl, trifluoromethyl, hydroxy, C₁₋₆ alkoxy, aryloxy, keto, C₁₋₃ alkylenedioxy, nitro, cyano, carboxy, C₂₋₆ alkoxycarbonyl, C₂₋₆ alkoxycarbonyl(C₁₋₆)alkyl, C₂₋₆ alkylcarbonyloxy, arylcarbonyloxy, C₂₋₆ alkylcarbonyl, arylcarbonyl, C₁₋₆ alkylthio, C₁₋₆ alkylsulphinyl, C₁₋₆ alkylsulphonyl, arylsulphonyl, trifluoromethane-sulphonyloxy, -NR^VR^W, -NR^VCOR^W, -NR^VCO₂R^W, -NR^VSO₂R^W, -CH₂NR^VSO₂R^W, -NHCONR^VR^W, -PO(OR^V)(OR^W), -CONR^VR^W, -SO₂NR^VR^W and -CH₂SO₂NR^VR^W, in which R^V and R^W independently represent hydrogen, C₁₋₆ alkyl, aryl or aryl(C₁₋₆)alkyl.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially chlorine.

The present invention includes within its scope prodrugs of the compounds of formula I above. In general, such prodrugs will be functional derivatives of the compounds of formula I which are readily convertible in vivo into the required compound of formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

- 8 -

The aromatic or heteroaromatic ring of which W is the residue is suitably a phenyl, naphthyl, furyl, thienyl, pyrrolyl or pyridyl ring, optionally substituted by one or more, preferably up to three, substituents.

5 Examples of optional substituents on the aromatic or heteroaromatic ring of which W is the residue include halogen, trifluoromethyl, cyano, nitro, amino, C₁₋₆ alkylamino, di(C₁₋₆)alkylamino, C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl(C₁₋₆)alkoxy and C₂₋₆ alkylcarbonyl.

10 Suitably, the aromatic or heteroaromatic ring of which W is the residue is unsubstituted. Where the ring is substituted, particular substituents include methyl, ethyl, isopropyl, methoxy, benzyloxy, fluoro and chloro.

15 Suitably, the substituents R¹ and R² independently represent hydrogen or methyl, especially hydrogen.

Suitable values for the substituents R³ and R⁴ include C₂₋₆ alkenyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl, aryl(C₁₋₆)alkyl and heteroaryl(C₁₋₆)alkyl, any of which groups may be optionally substituted. In addition, one of R³ and/or R⁴ may represent hydrogen. Examples of suitable substituents on the groups R³ and/or R⁴ include C₁₋₆ alkyl, halogen, C₁₋₆ alkoxy and nitro.


25 Particular values of R³ and R⁴ include hydrogen, allyl, cyclopropylmethyl, cyclohexylmethyl, benzyl, methyl-benzyl, chlorobenzyl, dichlorobenzyl, methoxy-benzyl, nitro-benzyl, naphthylmethyl, phenethyl, phenylpropyl and aza-indolylmethyl, provided that at least one of R³ and R⁴ is other than hydrogen. Suitably, one of R³ and R⁴ represents hydrogen, and the other of R³ and R⁴ is other than hydrogen. Preferably, R⁴ represents hydrogen and R³ is other than hydrogen.

Suitably, R⁵ is hydrogen or methyl.

- 9 -

Suitable values for the substituent R^6 include C_{1-6} alkyl, amino, C_{1-6} alkylamino and di(C_{1-6})alkylamino. A particular value of R^6 is amino.

5 A particular sub-class of compounds according to the invention is represented by the compounds of formula IIA, and salts and prodrugs thereof:



(IIA)

wherein

Z is as defined with reference to formula I above;

20 Y^1 represents oxygen or $N-R^{15}$;

R^{13} represents C_{2-6} alkenyl, C_{3-7} cycloalkyl(C_{1-6})alkyl, aryl(C_{1-6})alkyl or heteroaryl(C_{1-6})alkyl, any of which groups may be optionally substituted;

25 R^{15} represents hydrogen or C_{1-6} alkyl; and

R^{16} represents hydrogen, halogen, trifluoromethyl, cyano, nitro, amino, C_{1-6} alkylamino, di(C_{1-6})alkylamino, C_{1-6} alkyl, C_{1-6} alkoxy, aryl(C_{1-6})alkoxy or C_{2-6} alkylcarbonyl.

30 Examples of suitable substituents on the group R^{13} include one or more of C_{1-6} alkyl, halogen, C_{1-6} alkoxy and nitro.

Particular values of R^{13} with reference to formula IIA above include allyl, cyclopropylmethyl, 35 cyclohexylmethyl, benzyl, methyl-benzyl, chlorobenzyl, dichlorobenzyl, methoxy-benzyl, nitro-benzyl,

- 10 -


naphthylmethyl, phenethyl, phenylpropyl and aza-indolylmethyl.

Particular values of γ^1 with reference to formula IIA above include oxygen, NH and N-methyl.

5 Suitably, R^{15} is hydrogen or methyl.

Particular values of R^{16} include hydrogen, methyl, ethyl, isopropyl, methoxy, benzyloxy, fluoro and chloro, especially hydrogen.

10 Another sub-class of compounds according to the invention is represented by the compounds of formula IIB, and salts and prodrugs thereof:



(I I B)

wherein

25 X^1 represents oxygen or N- R^{15} ;

Z is as defined with reference to formula I above; and


R^{13} , R^{15} and R^{16} are as defined with reference to formula IIA above.

30 Particular values of X^1 include oxygen, NH and N-methyl.

A further sub-class of compounds according to the invention is represented by the compounds of formula IIC, and salts and prodrugs thereof:

35

- 11 -



(IIC)


10 wherein

Z is as defined with reference to formula I above; and

X¹, R¹³ and R¹⁶ are as defined with reference to formula IIA above.

15

Another particular sub-class of compounds according to the invention is represented by the compounds of formula IID, and salts and prodrugs thereof:



(IID)

wherein

30 Z is as defined with reference to formula I above;

R¹³ represents C₂₋₆ alkenyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl, aryl(C₁₋₆)alkyl or heteroaryl(C₁₋₆)alkyl, any of which groups may be optionally substituted;

35 R¹⁴ represents C₁₋₆ alkyl, amino, C₁₋₆ alkylamino or di(C₁₋₆)alkylamino; and

- 12 -

R^{16} represents hydrogen, halogen, trifluoromethyl, cyano, nitro, amino, C_{1-6} alkylamino, di(C_{1-6})alkylamino, C_{1-6} alkyl, C_{1-6} alkoxy, aryl(C_{1-6})alkoxy or C_{2-6} alkylcarbonyl.


5 Examples of suitable substituents on the group R^{13} include one or more of C_{1-6} alkyl, halogen, C_{1-6} alkoxy and nitro.

Particular values of R^{13} with reference to formula IID above include allyl, cyclopropylmethyl, 10 cyclohexylmethyl, benzyl, methyl-benzyl, chlorobenzyl, dichlorobenzyl, methoxy-benzyl, nitro-benzyl, naphthylmethyl, phenethyl, phenylpropyl and azaindolylmethyl.

A particular value of R^{14} is amino.

15 Particular values of R^{16} include hydrogen, methyl, ethyl, isopropyl, methoxy, benzyloxy, fluoro and chloro, especially hydrogen.

A further sub-class of compounds according to the invention is represented by the compounds of formula 20 IIE, and salts and prodrugs thereof:



(IIE)

wherein

Z is as defined with reference to formula I above; and

R^{13} , R^{14} and R^{16} are as defined with reference 35 to formula IID above.

- 13 -

Specific compounds within the scope of the present invention include:

- 3-[4-(2-phenylethyl)piperazin-1-yl]-4,5-dihydro-1H-benzo[g]indazole;
- 5 3-(4-benzylpiperazin-1-yl)-4,5-dihydro-1H-benzo[g]indazole;
- 3-[4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)piperazin-1-yl]-4,5-dihydro-1H-benzo[g]indazole;
- 3-(4-benzylpiperazin-1-yl)-4,5-dihydronaphth[1,2-c]-
- 10 isoxazole;
- 3-[4-(2-phenylethyl)piperazin-1-yl]-4,5-dihydronaphth[1,2-c]isoxazole;
- 3-[4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)piperazin-1-yl]-4,5-dihydronaphth[1,2-c]isoxazole;
- 15 3-[4-(2-phenylethyl)piperazin-1-yl]-4,5-dihydro-2-methyl-2H-benzo[g]indazole;
- 3-[4-(2-phenylethyl)piperazin-1-yl]-4,5-dihydro-1-methyl-1H-benzo[g]indazole;
- 3-[4-(2-phenylethyl)piperazin-1-yl]-4,5-dihydro-1H-
- 20 thieno[2,3-g]indazole;
- 3-(4-benzylpiperazin-1-yl)-1,4-dihydroindeno[1,2-c]pyrazole;
- 3-[4-(2-phenylethyl)piperazin-1-yl]-1,4-dihydroindeno[1,2-c]pyrazole;
- 25 3-(4-benzylpiperazin-1-yl)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazole;
- 3-[4-(2-phenylethyl)piperazin-1-yl]-1-methyl-1,4-dihydroindeno[1,2-c]pyrazole;
- 3-[4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)piperazin-1-yl]-1-methyl-1,4-dihydroindeno[1,2-c]pyrazole;
- 30 4-(4-benzylpiperazin-1-yl)-5H-indeno[1,2-d]pyrimidin-2-ylamine;
- 4-[4-(2-phenylethyl)piperazin-1-yl]-5H-indeno[1,2-d]pyrimidin-2-ylamine;
- 35 and salts and prodrugs thereof.

- 14 -

The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the compositions may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of

- 15 -



prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by
5 an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of
10 polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous
15 solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical
20 vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.

25 In the treatment of disorders of the dopamine system, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4
30 times per day.

The compounds in accordance with the present invention, wherein Q represents $=N-NR^5-$, $-NR^5-N=$, $=N-O-$ or $-O-N=$, may be prepared by a process which comprises reacting a compound of formula III with a compound of
35 formula IVa:

- 16 -



(IVa)

wherein W, Z, R¹, R² and R⁴ are as defined above, R³⁰ corresponds to the group R³ as defined above or represents an amino-protecting group, X^a represents oxygen or N-R⁵ in which R⁵ is as defined above, and L¹ represents a suitable leaving group; followed, where necessary, by removal of the amino-protecting group R³⁰; and subsequently, if required, attachment of the substituent R³ by conventional means.

The reaction is conveniently carried out by stirring the reactants in a suitable solvent, for example a C₁₋₄ alkanol such as ethanol or a mixture of N,N-dimethylformamide and methanol, optionally in the presence of a non-nucleophilic base such as ethyldiisopropylamine, suitably at room temperature.



Where the substituent R³⁰ represents an amino-protecting group, this group is suitably an acyl moiety such as t-butoxycarbonyl (BOC), which can conveniently be removed as necessary by treatment under acidic conditions, e.g. stirring in trifluoroacetic acid.

As will be appreciated, the overall reaction between compounds III and IVa will often give rise to a mixture of isomeric products of formula I, in one of which Q represents =N-NR⁵- or =N-O-, and in the other of which Q represents -NR⁵-N= or -O-N=. For this reason, it will generally be necessary at an appropriate stage to

- 17 -

separate the mixture of isomers obtained therefrom by conventional methods such as column chromatography.

The compounds in accordance with the present invention, wherein Q represents $=N-CR^6=N-$ may be prepared by a process which comprises reacting a compound of formula III with a compound of formula IVb:



wherein W , Z , R^1 , R^2 , R^4 and R^6 are as defined above, R^{30} corresponds to the group R^3 as defined above or represents an amino-protecting group, and L^1 represents a suitable leaving group; in the presence of a base; followed, where necessary, by removal of the amino-protecting group R^{30} ; and subsequently, if required, attachment of the substituent R^3 by conventional means.


The reaction is conveniently carried out by heating the reactants in a suitable solvent, typically at the reflux temperature. The base employed will suitably be a C_{1-4} alkoxide salt, in which case the reaction is conveniently effected in the corresponding C_{1-4} alkanol as solvent. Typically, the reaction may be carried out in the presence of approximately two equivalents of sodium isopropoxide, utilising isopropanol as the solvent.

Where the substituent R^{30} represents an amino-protecting group, this group is suitably an acyl moiety such as t-butoxycarbonyl (BOC), which can conveniently be


- 18 -

removed as necessary by treatment under acidic conditions, e.g. stirring in trifluoroacetic acid.

The intermediates of formula III above may be prepared by reacting a compound of formula V with a compound of formula VI:



(V)



(VI)

wherein W, Z, R¹, R², R³⁰ and L¹ are as defined above, and L² represents a suitable leaving group which may or may not be identical to L¹.


The reaction is conveniently effected by heating the reactants in an appropriate solvent, for example acetonitrile, suitably at the reflux temperature of the solvent employed.

The leaving groups L¹ and L², which may be the same or different, will suitably be conventional leaving groups well known from the art. For advantageous results, it has been found appropriate for L¹ and L² both to be C₁₋₄ alkylthio groups, especially methylthio.

Where L¹ and L² both represent C₁₋₄ alkylthio, the intermediates of formula V may be prepared by reacting a compound of formula VII:

35

- 19 -



(VII)

wherein W, Z, R¹ and R² are as defined above; with carbon disulphide and an appropriate C₁₋₄ alkyl halide, e.g. methyl iodide, in the presence of a base such as sodium hydride.

15 The reaction is conveniently effected by stirring the reactants at room temperature in a suitable solvent, for example tetrahydrofuran.

 Where they are not commercially available, the starting materials of formula VI and VII may be prepared
20 by procedures analogous to those described in the accompanying Examples, or by standard methods well known from the art.

 It will be appreciated that any compound of formula I initially obtained from any of the above
25 processes may, where appropriate, subsequently be elaborated into a further desired compound of formula I using techniques known from the art. For example, a compound of formula I wherein R³ is hydrogen initially obtained may be converted into a compound of formula I
30 wherein R³ represents C₁₋₆ alkyl by standard alkylation techniques, such as by treatment with an alkyl iodide, e.g. methyl iodide, typically under basic conditions, e.g. sodium hydride in N,N-dimethylformamide, or triethylamine in acetonitrile.

35 Where the above-described processes for the preparation of the compounds according to the invention

- 20 -

give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The following Examples illustrate the preparation of compounds according to the invention.

The compounds useful in this invention potentially inhibit [³H]-spiperone binding to human dopamine D₄ receptor subtypes expressed in clonal cell lines.

[³H]-Spiperone Binding Studies

Clonal cell lines expressing the human dopamine D₄ receptor subtype were harvested in PBS and then lysed in 10 mM Tris-HCl pH 7.4 buffer containing 5 mM MgSO₄ for

- 21 -

20 min on ice. Membranes were centrifuged at 50,000g for 15 min at 4°C and the resulting pellets resuspended in assay buffer (50 mM Tris-HCl pH 7.4 containing 5 mM EDTA, 1.5 mM CaCl₂, 5 mM MgCl₂, 5 mM KCl, 120 mM NaCl, and 0.1% ascorbic acid) at 20 mg/ml wet weight. Incubations were carried out for 60 min at room temperature (22°C) in the presence of 0.05-2 nM [³H]-spiperone or 0.2 nM for displacement studies and were initiated by addition of 20-100 µg protein in a final assay volume of 0.5 ml. The incubation was terminated by rapid filtration over GF/B filters presoaked in 0.3% PEI and washed with 10 ml ice-cold 50 mM Tris-HCl, pH 7.4. Specific binding was determined by 10 µM apomorphine and radioactivity determined by counting in a LKB beta counter. Binding parameters were determined by non-linear least squares regression analysis, from which the inhibition constant K_i could be calculated for each test compound.

The compounds of the accompanying Examples were tested in the above assay, and all were found to possess a K_i value for displacement of [³H]-spiperone from the human dopamine D₄ receptor subtype of below 1.5 µM.

EXAMPLE 13-(4-(2-Phenylethyl)piperazin-1-yl)-4,5-dihydro-1H-benzo[glindazole.

5

Sodium hydride (60% in oil, 35 g, 880 mmol) was added with care to a solution of 1-tetralone (54 g, 370 mmol), carbon disulfide (27 ml, 33.7 g, 443 mmol), and methyl iodide (52 ml, 115 g, 810 mmol) in THF (400 ml) at 0°C. The mixture was stirred at room temperature overnight, giving a yellow solution with a white precipitate. Saturated aqueous ammonium chloride solution and ethyl acetate were added, the mixture separated, and the organic layer washed with water and brine, dried (MgSO₄), evaporated *in vacuo*, and the resulting solid recrystallised from ethyl acetate / hexanes to give 2-(bis-methylthiomethylene)-4,5-dihydro-2H-naphthalen-1-one (67 g, 59%) as yellow cubes, m.p. 54-56°C; δ (360 MHz, CDCl₃) 2.43 (6 H, br s, Me), 2.98 (2 H, t, J = 6.7 Hz, CH₂), 3.26 (2 H, t, J = 6.7 Hz, CH₂), 7.22 (1 H, d, J = 7.6 Hz, H-5), 7.32 (1 H, t, J = 7.6 Hz, H-7), 7.43 (1 H, dt, J = 1.2 and 7.6 Hz, H-6), 8.10 (1 H, dd, J = 1.2 and 7.6 Hz, H-8).

2-(Bis-methylthiomethylene)-4,5-dihydro-2H-naphthalen-1-one (11.56 g, 46 mmol) and 1-*tert*-butyloxycarbonylpiperazine (10.3 g, 55 mmol) were refluxed in acetonitrile (300 ml) for 24 h. The mixture was cooled, water (500 ml) added, and extracted with ethyl acetate (3 x 200 ml). The combined organics were washed with water and brine, dried (MgSO₄), evaporated *in vacuo*, and the resulting oil purified by flash chromatography, eluting with dichloromethane then dichloromethane : methanol (97 : 3 v/v) to give 2-(methylthio[4-(*tert*-butyloxycarbonyl)-1-

30

piperazinyl)methylene)-4,5-dihydro-2H-naphthalen-1-one (8.75 g, 49%) as a foam; δ (360 MHz, CDCl_3) 1.49 (9H, s, ^tBu), 3.31 (3 H, s, MeS), 2.86-2.94 (4 H, m, $\text{CCH}_2\text{CH}_2\text{C}$), 3.3-3.5 (8 H, m, $\text{NCH}_2\text{CH}_2\text{N}$), 7.18 (1 H, d, $J = 7.5$ Hz, H-5), 7.30 (1 H, t, $J = 7.5$ Hz, H-7), 7.37 (1 H, dt, $J = 1.4$ and 7.5 Hz, H-6), 8.10 (1 H, dd, $J = 1.4$ and 7.5 Hz, H-8).

2-(Methylthio[4-(*tert*-butyloxycarbonyl)-1-piperazinyl)methylene)-4,5-dihydro-2H-naphthalen-1-one (5.3 g, 13.7 mmol) and hydrazine hydrate (3.4 g, 68.5 mmol) were stirred in ethanol (100 ml) at room temperature for 16 h. The solvent was evaporated *in vacuo*, and the resulting oil purified by flash chromatography, eluting with dichloromethane : methanol (95 : 5 v/v) to give 3-(4-(*tert*-butyloxycarbonylpiperazin-1-yl)-4,5-dihydro-1H-benzo[g]lindazole (3.9 g, 80 %) as a yellow oil; δ (360 MHz, CDCl_3) 1.48 (9 H, s, ^tBu), 2.72 (2 H, t, $J = 7.7$ Hz, $\text{CCH}_2\text{CH}_2\text{C}$), 2.95 (2 H, t, $J = 7.7$ Hz, $\text{CCH}_2\text{CH}_2\text{C}$), 3.13 (4 H, t, $J = 5.2$ Hz, NCH_2), 3.53 (4 H, t, $J = 5.2$ Hz, NCH_2), 7.2-7.4 (4 H, m, ArH).

3-(4-(*tert*-Butyloxycarbonylpiperazin-1-yl)-4,5-dihydro-1H-benzo[g]lindazole (1.65 g, 4.8 mmol) was dissolved in trifluoroacetic acid (10 ml). After 30 min the solvent was evaporated *in vacuo* to give 3-(piperazin-1-yl)-4,5-dihydro-1H-benzo[g]lindazole *bis*-trifluoroacetate, which still contained an excess amount of trifluoroacetic acid (2.64 g), as a light brown solid; δ (360 Mhz, $\text{d}_6\text{-DMSO}$) 2.66 (2 H, t, $J = 7.2$ Hz, $\text{CCH}_2\text{CH}_2\text{C}$), 2.95 (2 H, t, $J = 7.2$ Hz, $\text{CCH}_2\text{CH}_2\text{C}$), 3.22 (4 H, br s, NCH_2), 3.30 (4 H, br s, NCH_2), 7.2-7.3 (3 H, m, ArH), 7.56 (1 H, d, $J = 6.6$ Hz, H-9), 8.8 (2H, br s, NH^+). This was used crude in the next reaction.

3-(Piperazin-1-yl)-4,5-dihydro-1H-benzo[g]indazole bis-trifluoroacetate (416 mg, 1.1 mmol), ethyldiisopropylamine (590 µl, 430 mg, 3.3 mmol), and 2-phenethyl bromide (168 µl, 228 mg, 1.23 mmol) were heated in DMF (3 ml) at 60 °C for 4 h. The mixture was cooled, diluted with water (20 ml), extracted with ethyl acetate (3 x 10 ml), the combined organic fractions washed with brine, dried (MgSO₄), and evaporated *in vacuo*. The resulting light brown oil was dissolved in ethanol (2 ml), heated to boiling, and oxalic acid (1.3 ml of a 1M solution in ethanol) added. After cooling to room temperature the resulting solid was collected, washed with ethanol, and recrystallised from DMF : ethanol (1 :9 v/v) to give 3-(4-(2-phenylethyl)piperazin-1-yl)-4,5-dihydro-1H-benzo[g]indazole oxalate salt (98 mg, 30 % over two steps) as white needles mp 216-219 °C (Found: C, 66.55; H, 6.32; N, 12.30. C₂₃H₂₄N₄ C₂O₄H₂ requires C, 66.94; H, 6.29; N, 12.49%); δ (360 MHz, d₆-DMSO) 2.66 (2 H, t, *J* = 7.6 Hz, CCH₂CH₂C), 2.87 (2 H, t, *J* = 7.6 Hz, CCH₂CH₂C), 2.88 (2 H, t *J* = 7 Hz, PhCH₂), 3.1-3.2 (6H, m, CH₂), 3.25 - 3.4 (4 H, m, CH₂), 7.1-7.4 (8 H, m, ArH), 7.55 (1 H, d, *J* = 6.7 Hz, H-9); *m/z* (CI⁺, NH₃) 359 (*M*⁺ + H).

EXAMPLE 2

3-(4-Benzylpiperazin-1-yl)-4,5-dihydro-1H-benzo[g]indazole: oxalate salt, white microcrystalline solid, mp 254-256°C (from EtOH) (Found: C, 65.71; H, 6.04; N, 12.40. C₂₂H₂₄N₄·C₂H₂O₄·0.25H₂O requires C, 65.66; H, 6.08; N, 12.76%); δ (360MHz, d₆-DMSO) 2.63 (2H, t, = 7.6Hz, CCH₂CH₂C), 2.86 (2H, t, *J* = 7.6Hz, CCH₂CH₂C), 2.96 (4H, br s, NCH₂), 3.26 (4H, br s, NCH₂), 4.04 (2H, s, PhCH₂), 7.1-7.3 (3H, m, ArH), 7.4-7.5 (5H, m, ArH), 7.54 (1H, d, *J* = 6.7Hz, H-9); *m/z* (CI⁺, NH₃) 345 (*M*⁺+H).

EXAMPLE 33-(4-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-piperazin-1-yl)-
4,5-dihydro-1H-benzo[g]indazole

5

3-(Piperazin-1-yl)-4,5-dihydro-1H-benzo[g]indazole *bis*-trifluoroacetate (708mg, 2mmol), ethyldiisopropylamine (700 μ l, 511mg, 4mmol) and 3-dimethylaminomethyl-1H-pyrrolo[2,3-b]pyridine (175mg, 1mmol) were heated in toluene (4ml) and DMF (2ml) at 100°C for 3h. The mixture was cooled, water (20ml) added, and the mixture extracted with ethyl acetate (3 x 15ml). The combined organic extracts were washed with brine, dried and evaporated *in vacuo* to give a brown solid, which was suspended in boiling methanol (4ml), then cooled. The liquid was removed, and the solid recrystallised from aqueous methanol to give the title compound (53mg, 7%) as a white microcrystalline solid, mp 245-247°C (Found: C, 71.4; H, 6.35; N, 21.31. C₂₃H₂₄N₆·0.25H₂O requires C, 71.02; H, 6.35; N, 21.60%); δ (360MHz, d₆-DMSO) 2.5-2.55 (4H, m, NCH₂), 2.61 (2H, t, *J* = 7.5Hz, CCH₂CH₂C), 2.84 (2H, t, *J* = 7.5Hz, CCH₂CH₂C), 3.05-3.10 (4H, m, NCH₂), 3.68 (2H, s, NCH₂C), 7.04 (1H, dd, *J* = 4.7 and 7.8Hz, NCHCH), 7.1-7.3 (3H, m, ArH), 7.37 (1H, s, CHNH), 7.52 (1H, d, *J* = 7.8Hz, CHCHCHN), 8.05 (1H, d, *J* = 6.6Hz, H-9), 8.19 (1H, d, *J* = 4.7Hz, NCHCH), 11.46 (1H, s, NH), 12.20 (1H, s, NH); *m/z* (CI⁺, NH₃) 385 (M⁺+H).

10

15

20

25

EXAMPLE 43-(4-Benzylpiperazin-1-yl)-4,5-dihydronaphth[1,2-clisoxazole

5 2-(Methylthio[4-(*tert*-butyloxycarbonyl)piperazin-1-yl]methylene)-4,5-dihydro-2H-naphthalen-1-one (70mg, 185 μ mol), hydroxylamine hydrochloride (139mg, 2mmol) and ethyldiisopropylamine (350 μ l, 256mg, 2mmol) were stirred in ethanol (2ml) for 16h. Water (10ml) was added, and the mixture
10 extracted with ethyl acetate (3 x 10ml). The combined organic layers were washed with brine, dried, evaporated *in vacuo*, and purified by preparative thin layer chromatography to give 3-[3-(*tert*-Butyloxycarbonyl)piperazin-1-yl)-4,5-dihydronaphth[1,2-clisoxazole as a white solid (49mg, 77%); δ (360MHz, CDCl₃) 1.48 (9H, s, *t*Bu), 2.78 (2H, t, *J* = 7.9Hz, CCH₂CH₂C), 3.04 (2H, t, *J* = 7.9Hz, CCH₂CH₂C), 3.29 (4H, t, *J* = 5.4Hz, NCH₂), 3.57 (4H, t, *J* = 5.4Hz, NCH₂), 7.2-7.3 (3H, m, ArH), 7.6-7.65 (1H, m, H-9). This was taken on in the same way as Example 1 to give the title
15 compound as white cubes, mp 148-149°C (from ethyl acetate) (Found: C, 76.12; H, 6.61; N, 11.99. C₂₂H₂₃NO requires C, 76.49; H, 6.71; N, 12.16%); δ (360MHz, d₆-DMSO) 2.45-2.50 (4H, m, NCH₂, partially under DMSO peak), 2.75 (2H, t, *J* = 7.5Hz, CCH₂CH₂C), 2.99 (2H, t, *J* = 7.5Hz, CCH₂CH₂C), 3.22 (4H, t, *J* = 4.8Hz, NCH₂), 3.52 (2H, s, NCH₂Ph), 7.2-7.4 (8H, m, ArH), 7.50
20 (1H, d, *J* = 7.6Hz, H-9); *m/z* (CI⁺, NH₃) 346 (M⁺+H).
25

EXAMPLE 53-[4-(2-Phenylethyl)piperazin-1-yl]-4,5-dihydronaphth[1,2-clisoxazole

5

Light brown crystals mp 134-136°C (from ethyl acetate/hexanes) (Found: C, 75.78; H, 6.84; N, 11.56. $C_{23}H_{25}N_3O \cdot 0.25H_2O$ requires C, 75.89; H, 7.06; N, 11.55%); δ (360MHz, d_6 -DMSO) 2.55-2.60 (6H, m, CH_2 's), 2.75-2.80 (4H, m, CH_2 's), 2.99 (2H, t, $J = 7.8$ Hz, CCH_2CH_2C), 3.23 (4H, t, $J = 4.7$ Hz, NCH_2), 7.1-7.4 (8H, m, ArH), 7.50 (1H, dd, $J = 2.1$ and 6Hz, H-9), m/z (CI^+ , NH_3) 360 ($M^+ + H$).

10

EXAMPLE 6

15

3-[4-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-piperazin-1-yl]-4,5-dihydronaphth[1,2-clisoxazole

20

White plates, mp 248-250°C (from methanol) (Found: C, 71.26; H, 6.03; N, 17.81. $C_{23}H_{23}N_5O$ requires C, 71.66; H, 6.01; N, 18.17%); δ (360MHz, d_6 -DMSO) 2.45-2.50 (4H, m, NCH_2 , partially obscured by DMSO), 2.74 (2H, t, $J = 7.8$ Hz, CCH_2CH_2C), 3.20 (4H, t, $J = 4.4$ Hz, NCH_2), 3.69 (2H, s, NCH_2), 7.04 (1H, dd, $J = 4.7$ and 7.9Hz, $CHCHN$), 7.25-7.35 (3H, m, ArH), 7.37 (1H, s, $CHNH$), 7.50 (1H, d, $J = 7.9$ Hz, $CHCHCHN$), 8.05 (1H, d, $J = 6.6$ Hz, H-9), 8.20 (1H, d, $J = 4.7$ Hz, $CHCHN$), 11.47 (1H, s, NH); m/z (CI^+ , NH_3) 386 ($M^+ + H$).

25

EXAMPLES 7 AND 8

5 3-(4-(2-Phenylethyl)piperazin-1-yl)-4,5-dihydro-2-methyl-2H-benzo[g]indazole and 3-(4-(2-Phenylethyl)piperazin-1-yl)-4,5-dihydro-1-methyl-1H-benzo[g]indazole

10 2-(Methylthio(4-(*tert*-butyloxycarbonyl)piperazin-1-yl)methylene-4,5-dihydro-2H-naphthalen-1-one (3.2g, 8.2mmol) and methylhydrazine (5ml) were kept in ethanol (30ml) for four days. Water (150ml) was added, and the mixture extracted with ethyl acetate (3 x 50ml). The combined organic layers were washed with brine, dried (MgSO₄), evaporated *in vacuo*, and purified by flash chromatography, eluting with hexane:ethyl acetate (4:1 v/v) to give 3-(4-(*tert*-butyloxycarbonyl)piperazin-1-yl)-4,5-dihydro-1-methyl-1H-benzo[g]indazole (342mg, 11%) as a colourless oil; ¹H NMR (360MHz, CDCl₃) δ 1.52 (9H, s, ^tBu), 2.67 (2H, t, *J* = 7.3Hz, CCH₂CH₂C), 2.94 (2H, t, *J* = 7.3Hz, CCH₂CH₂C), 3.15 (4H, t, *J* = 5.1Hz, NCH₂), 3.61 (4H, t, *J* = 5.1Hz, NCH₂), 4.15 (3H, s, Me), 7.22-7.34 (3H, m, ArH), 7.55 (1H, d, *J* = 7.7Hz, H-9). Irradiation at δ 4.15 gave a positive nOe to the doublet at δ 7.55, and the reverse; and 3-(4-(*tert*-butyloxycarbonyl)piperazin-1-yl)-4,5-dihydro-2-methyl-2H-benzo[g]indazole (561mg, 19%) as a white solid δ (360MHz, CDCl₃) 1.54 (9H, s, ^tBu), 2.86 (2H, t, *J* = 7.8Hz, CCH₂CH₂C), 2.95 (2H, t, *J* = 7.8Hz, CCH₂CH₂C), 3.08 (4H, t, *J* = 4.9Hz, NCH₂), 3.60 (4H, t, *J* = 4.9Hz, NCH₂), 7.20-7.30 (3H, m, ArH), 7.83 (1H, d, *J* = 7.5Hz, H-9).

30 These were taken on as for Example 1 to give 3-(4-(2-phenylethyl)piperazin-1-yl)-4,5-dihydro-2-methyl-2H-benzo[g]indazole oxalate salt, mp 244-245°C (from ethanol).

(Found: C, 66.94; H, 6.42; N, 11.71. $C_{24}H_{28}N_4 \cdot C_2H_2O_4 \cdot 0.2H_2O$ requires C, 66.99; H, 6.57; N, 12.02%); δ (360MHz, d_6 -DMSO) 2.8-2.9(4H, m, CCH₂CH₂C), 2.90-2.95 (2H, m, CH₂), 3.1-3.2 (6H, m, CH₂'s), 3.2-3.25 (4H, m, CH₂'s), 3.69 (3H, s, Me), 7.1-7.4 (8H, m, ArH), 7.61 (1H, d, $J = 7.7$ Hz, H-9); m/z (CI⁺, NH₃) 373 ($M^+ + H$), and 3-(4-(2-phenylethyl)piperazin-1-yl)-4,5-dihydro-1-methyl-1H-benzo[g]lindazole oxalate salt, mp 225-226°C (from ethanol) (Found: C, 67.04; H, 6.66; N, 11.92.

$C_{24}H_{28}N_4 \cdot C_2H_2O_4 \cdot 0.2H_2O$ requires C, 66.99; H, 6.57; N, 12.01%); δ (360MHz, d_6 -DMSO) 2.56 (2H, t, $J = 7.7$ Hz, CCH₂CH₂C), 2.83 (2H, t, $J = 7.7$ Hz, CCH₂CH₂C), 2.95 (2H, t, $J = 8$ Hz, PhCH₂), 3.1-3.2 (6H, m, CH₂'s), 3.25-3.35 (4H, m, CH₂'s), 3.95 (3H, s, Me), 7.2-7.4 (8H, m, ArH), 7.63 (1H, d, $J = 7.1$ Hz, H-9); m/z (CI⁺, NH₃) 373 ($M^+ + H$).

EXAMPLE 9

3-(4-(2-Phenylethyl)piperazin-1-yl)-4,5-dihydro-1H-thieno[2,3-g]lindazole

Oxalate salt, white plates, mp 145-147°C (from ethanol) (Found: C, 58.99; H, 5.73; N, 11.89. $C_{21}H_{24}N_4S \cdot C_2H_2O_4 \cdot 0.8H_2O$ requires C, 58.91; H, 5.93; N, 11.95%); δ (360MHz, d_6 -DMSO) 2.76 (2H, t, $J = 7.7$ Hz, CH₂), 2.9-3.0 (4H, m, CH₂'s), 3.1-3.2 (6H, m, CH₂'s), 3.2-3.3 (4H, m, CH₂'s), 7.20-7.35 (6H, m, ArH), 7.39 (1H, d, $J = 5.1$ Hz, ArH); m/z (CI⁺, NH₃), 365 ($M^+ + H$).

EXAMPLE 103-(4-Benzylpiperazin-1-yl)-1,4-dihydroindeno[1,2-c]pyrazole

5 Off white crystals, mp 256-258°C (from DMF/Ether) (Found: C, 64.40; H, 5.57; N, 12.86. $C_{21}H_{22}N_4 \cdot C_2H_2O_4 \cdot 0.5H_2O$ requires C, 64.32; H, 5.87; N, 13.05%) δ (360MHz, d_6 -DMSO) 2.8-2.9 (4H, m, CH_2N), 3.3-3.4 (4H, m, CH_2N), 3.60 (2H, s, $ArCH_2$), 3.84 (2H, s, $ArCH_2N$), 7.23 (1H, t, $J = 7.4$ Hz, ArH), 7.32 (1H, t, $J = 7.4$ Hz, ArH), 7.36-7.52 (7H, m, ArH), m/z (Cl^+ , NH_3) 331 (M^++H).

10

EXAMPLE 113-(4-(2-Phenylethyl)piperazin-1-yl)-1,4-dihydroindeno[1,2-c]pyrazole

15 Oxalate salt, off white crystals, mp 212-214°C (from methanol/ether) (Found: C, 65.58; H, 6.04; N, 12.34. $C_{22}H_{24}N_4 \cdot 1.1 \cdot C_2H_2O_4$ requires C, 66.54; H, 5.95; N, 12.63%) δ (360MHz, d_6 -DMSO) 2.93-2.98 (2H, m, $ArCH_2CH_2$), 3.09-3.44 (6H, m, $ArCH_2CH_2$ and NCH_2), 3.4-3.5 (4H, m, NCH_2), 3.63 (2H, s, $ArCH_2Ar$), 7.21-7.35 (7H, m, ArH), 7.51 (2H, t, $J = 7.2$ Hz, ArH m to CH_2CH_2) m/z (Cl^+ , NH_3) 345 (M^++H).

20

EXAMPLE 123-(4-Benzylpiperazin-1-yl)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazole

25 Oxalate salt, pale yellow crystals, mp 216-220°C (from ethanol) (Found: C, 63.09; H, 5.63; N, 11.74. $C_{22}H_{24}N_4 \cdot 1.4 \cdot C_2H_2O_4$ requires C, 63.31; H, 5.74; N, 11.91%) δ (360MHz, d_6 -DMSO) 2.86 (1H, br s, NCH_2CH_2), 3.32 (4H, br s,

30

NCH₂CH₂), 3.58 (2H, s, ArCH₂C), 3.90 (3H, s, CH₃), 3.92 (2H, s, ArCH₂N), 7.24-7.43 (7H, m, ArH), 7.50 (1H, d, $J = 7.5\text{Hz}$, ArH), 7.68 (1H, d, $J = 7.5\text{Hz}$, ArH) m/z (CI⁺, NH₃) 345 (M^{++H}).

Regiochemistry of Me group determined by NOE experiment
carried out on an earlier intermediate.

EXAMPLE 13

3-(4-(1-Phenylethyl)piperazin-1-yl)-1-methyl-1,4-dihydroindenof[1,2-c]pyrazole

Pale yellow crystals, mp 138-139°C (from ethanol) (Found: C, 76.87; H, 7.14; N, 15.47. C₂₃H₂₆N₄ requires C, 77.06; H, 7.31; N, 15.63%) δ (360MHz, d₆-DMSO), 2.53-2.58 (6H, m, ArCH₂CH₂), 2.74-2.79 (2H, m, ArCH₂C), 3.19-3.22 (4H, m, NCH₂CH₂), 3.59 (2H, s, ArCH₂C), 3.89 (3H, s, CH₃), 7.16-7.36 (7H, m, ArH), 7.49 (1H, d, $J = 7.4\text{Hz}$, ArH), 7.67 (1H, d, $J = 7.4\text{Hz}$, ArH) m/z (CI⁺, NH₃) 359 (M^{++H}). Regiochemistry of Me group determined by NOE experiments carried out on an earlier intermediate.

EXAMPLE 14

3-(4-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)piperazin-1-yl)-1-methyl-4-dihydroindenof[1,2-c]pyrazole

Pale yellow needles, mp 235-240°C (from DMF) (Found: C, 70.85; H, 6.50; N, 21.61. C₂₃H₂₄N₆·0.3H₂O requires C, 70.85; H, 6.36; N, 21.55%) δ (360MHz, d₆-DMSO) 2.49-2.51 (4H, m, NCH₂), 3.2 (4H, brs, NCH₂), 3.56 (2H, s, ArCH₂), 3.67 (2H, s, ArCH₂), 3.95 (3H, s, CH₃), 7.04 (1H, dd, $J = 7.8\text{Hz}$ and $J = 4.7\text{Hz}$, NCHCHCH), 7.22 (1H, td, $J = 7.5\text{Hz}$ and 1.1Hz , ArH), 7.34 (1H,

td, $J = 7.5\text{Hz}$ and 1.1Hz , ArH), 7.38 (1H, d, $J = 2.3\text{Hz}$, NHCHH),
7.48 (1H, d, $J = 7.4\text{Hz}$, ArH), 7.66 (1H, d, $J = 7.4\text{Hz}$, ArH), 8.05
(1H, dd, $J = 7.8$ and 1.3Hz , NCHCHCHH), 8.20 (1H, dd, $J = 4.7\text{Hz}$
and 1.5Hz , NCHHCHCH), 11.4 (1H, br s, NH) m/z (Cl^+ , NH_3) 385
5 ($\text{M}^+ + \text{H}$). Regiochemistry of Me group determined by NOE
experiment carried out on an earlier intermediate.

10

15

20

25

30

- 33 -

EXAMPLE 15

3-(1-(4-(2-Phenylethyl)piperazinyl))-4,5-dihydro-6,8-dimethyl-1H-benzo[*q*]indazole

5 Cream coloured needles, m.p. 177-179°C (from EtOH-Hexane) (Found: C, 76.9; H, 7.8; N, 14.2. $C_{25}H_{30}N_4 \cdot 0.2(H_2O)$ requires C, 77.0; H, 7.9; N, 14.4%). δ_H (360 MHz; $CDCl_3$) 2.29 (3H, s, ArMe), 2.30 (3H, s, ArMe), 2.65-2.77 (8H, m, 3 x NCH_2 and $ArCH_2$), 2.83-2.88
10 (4H, m, 2 x $ArCH_2$), 3.31 (4H, t, $J=5Hz$, 2 x NCH_2), 6.92 (1H, s, ArH), 7.06 (1H, broad s, ArH) and 7.18-7.31 (5H, m, Ph); m/z (CI^+ ; NH_3) 387 ($M^+ + H$).

15 EXAMPLE 16

3-(1-(4-(2-(3-Phenylpropyl))piperazinyl))-4,5-dihydro-1H-benzo[*q*]indazole

20 White amorphous solid, m.p. 170-172°C (from EtOH) (Found: C, 59.6; H, 5.9; N, 10.0. $C_{24}H_{28}N_4 \cdot 2(CO_2H)_2 \cdot 0.67(H_2O)$ requires C, 59.6; H, 6.0; N, 9.9%). δ_H (360 MHz; $DMSO + CF_3CO_2H$) 1.17 (3H, d, $J=7Hz$, $NCHCH_3$), 2.70-2.78 (3H, m, $NCHCH_3$ and $ArCH_2$), 2.95 (2H, t, $J=7Hz$, $ArCH_2$), 3.22-3.48 (4H, m, 2 x NCH_2), 3.56-3.90
25 (6H, m, 2 x NCH_2 and $ArCH_2$), 7.30-7.40 (8H, m, 8 of ArH), 7.64 (1H, d, $J=6Hz$, 1 of ArH) and 9.90 (1H, broad s, NH); m/z (CI^+ ; NH_3) 390 ($M^+ + NH_4$), 373 ($M^+ + H$).

30 EXAMPLE 17

3-(4-(2-Phenylethyl)piperazin-1-yl)-1,4,5,6-tetrahydro-1,2-diazabenz[e]azulene

35 White needles, m.p. 147-148°C (from ethyl acetate : hexane) (Found: C, 76.56; H, 7.62; N, 14.80. $C_{24}H_{28}N_4 \cdot 0.2(H_2O)$ requires C, 76.64; H, 7.61; N, 14.90).

- 34 -

5 δ (360 MHz; δ_6 -DMSO) 1.89 (2H, quintet, $J=5\text{Hz}$, $\text{CH}_2\text{CH}_2\text{CH}_2$), 2.55-2.7 (10H, m, CH_2 's), 2.76-2.82 (2H, m, CH_2), 3.00-3.05 (2H, m, CH_2), 3.25-3.35 (2H, m, CH_2), 7.1-7.25 (8H, m, ArH), 7.69 (1H, d, $J=7\text{Hz}$, H-10), 12.1 (1H, s, NH); m/z (Cl^+ ; NH_3) 373 (M^++H).

EXAMPLE 18

10 1-Ethyl-3-(4-(2-phenylethyl)piperazin-1-yl)-4,5-dihydrobenzo[g]indazole

Oxalate salt, white solid, m.p. 193-195°C (from ethanol) (Found: C, 66.91; H, 6.49; N, 10.98. $\text{C}_{25}\text{H}_{30}\text{N}_4 \cdot 1.2(\text{C}_2\text{H}_2\text{O}_4)$ requires C, 66.54; H, 6.60; N, 11.33%). δ_{H} (360 MHz; δ_6 -DMSO) 1.35 (3H, t, $J=7.2\text{Hz}$, CH_3), 2.58-2.64 (2H, m, CH_2), 2.80-2.90 (2H, m, CH_2), 2.95-3.00 (2H, m, CH_2), 3.1-3.4 (10H, m, CH_2 's), 4.28 (2H, q, $J=7.2\text{Hz}$, CH_2CH_3), 7.2-7.4 (8H, m, ArH), 7.51 (1H, d, $J=7.8\text{Hz}$, ArH-9); irradiation of the signal at 4.28 gives a positive nOe to the signal at 7.51 ppm; m/z (Cl^+ ; NH_3) 387 (M^++H).

EXAMPLE 19

25 3-(4-(2-(5-Methylfuran-2-yl)ethyl)piperazin-1-yl)-4,5-dihydrobenzo[g]indazole

5-methyl furan-2-acetic acid

To a solution of potassium cyanide (12.2g, 0.187mol) and sodium carbonate (36g, 0.338mol) in water (250ml) was added 5-methyl furfural (7.5ml, 75mmol) in 1,4-dioxane (12ml) followed by glyoxal busulphite (3.0g, 0.289mol) and water (240ml). After stirring for 2½hr at room temperature, the reaction was worked up by adding 5N HCl(aq) to the reaction mixture carefully (HCN^\dagger) until the pH fell to $\approx 1-2$. Stirring was continued for 1hr after which time, no more gas was evolved.

- 35 -

Products were extracted with chloroform (3 x 150ml). Combined organics were washed with brine before being dried over Na₂SO₄ and concentrated in vacuo.

A brown solid was afforded (8.1g, 78%). δ_H (250 MHz, CDCl₃), 2.26 (3H, s, ArCH₃), 3.66 (2H, s, ArCH₂), 5.90 (1H, d, J=5Hz, ArH), 6.12 (1H, d, J=5Hz, ArH).

10 3-(4-(5-methylfuranyl)acetylpiperazin-1-yl)-4,5-dihydro-1H-benzo[g]indazole

To a solution of 3-piperazin-1-yl-4,5-dihydro-1H-benzo[g]indazole bistrifluoroacetate (450mg, 0.94mmol) and Hünigs base (664 μ l, 3.76mmol) in dichloromethane (25ml), was added 5-methylfuranyl-2-acetic acid (131mg, 0.94mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (200mg, 1.04mmol) and hydroxybenzotriazole (140mg, 1.04mmol). The reaction was stirred for 4hr at room temperature under nitrogen. The reaction mixture was poured into sodium bicarbonate solution and extracted with ethyl acetate (2 x 50ml). The combined organics were washed with water and brine before being dried over Na₂SO₄ and concentrated in vacuo. The residue was chromatographed through silica eluting with 5% MeOH/DCM/1% NH₃(aq) (v/v) to give the title compound as a pale brown crystalline solid (180mg, 51%). δ_H (250 MHz, d₆-DMSO), 2.24 (3H, s, ArCH₃), 2.65 (2H, t, J=3.8Hz, CCH₂CH₂C), 2.65 (2H, t, J=3.8Hz, CCH₂CH₂C), 3.05 (4H, br s, NCH₂CH₂N), 3.64 (4H, br s, NCH₂CH₂N), 3.74 (2H, s, ArCH₂C), 5.98 (1H, d, J=5Hz, ArCH), 6.06 (1H, d, J=5Hz, ArH), 7.14-7.33 (3H, m, ArH), 7.52 (1H, d, J=7.0Hz, ArH), 12.40 (1H, br s, NH).

- 36 -

3-(4-(2-(5-Methylfuran-2-yl)ethyl)piperazin-1-yl)-4,5-dihydrobenzo[g]indazole

To a solution of 3-(4-(5-methylfuranyl)acetyl piperazin-1-yl)-4,5-dihydro-1H-benzo[g]indazole (170mg),
5 0.45mmol) in tetrahydrofuran (25ml) was added LiAlH₄ (1.0M in THF) (680μl, 0.68mmol) slowly at room temperature under N₂. Stirring was continued for 1hr.

Reaction mixture was worked up by cautious addition of 20% NaOH(aq) until no further gas was
10 evolved. More water was then added (30ml) and the mixture extracted with ethyl acetate (2 x 50ml). Combined organics were washed with water and brine before being dried over Na₂SO₄ and concentrated in vacuo. The oily residue was chromatographed on silica preparative
15 TLC plates eluting with 4% MeOH/DCM/1% NH₃(aq) (v/v) to give purified title compound. (104 mg, ≈99%) as pale yellow crystals, m.p. 150-152°C (Found; C, 71.95; H, 7.37; N, 15.01. C₂₂H₂₆N₄O·0.3(H₂O) requires C, 71.83; H, 7.29; N, 15.23%); δH (360 MHz, d₆-DMSO), 2.21 (3H, s, OCCH₃), 2.44-2.66 (4H, m, CH₂), 2.74 (2H, tr, J=7.4Hz, CH₂), 2.86 (2H, t, J=7.4Hz, CH₂), 3.08 (4H, br s, NCH₂), 5.93 (1H, s, OCCH), 5.98 (1H, s, OCCH), 7.15-7.27 (3H, m, ArH), 7.52 (1H, br d, J=7.0Hz, ArH), 12.23 (1H, br s, NH) m/z (CI⁺, NH₃) 363 (M⁺+H).

25

EXAMPLE 20

2-Methyl-3-(4-(2-phenylethyl)piperazin-1-yl)-4,5,6-tetrahydro-1,2-diazabenz[e]azulene

30 Oxalate salt, white crystals, m.p. 225-228°C (from ethanol) (Found; C, 68.28; H, 6.73; N, 11.61. C₂₅H₃₀N₄·(COOH)₂ requires C, 68.05; H, 6.77; N, 11.76%); δH (360 MHz, d₆-DMSO), 1.94 (2H, m, CH₂CH₂CH₂), 2.75 (4H, m, CH₂), 2.94 (2H, m, CH₂), 3.10 (6H, m, CH₂), 3.27 (4H, br s, CH₂), 3.72 (3H, s, NCH₃), 7.14-7.36 (8H, m, ArH),
35 7.87 (1H, d, J=7.3Hz, ArH) m/z (CI⁺, NH₃) 387 (M⁺+H).

- 37 -

EXAMPLE 21

5 3-(4-(2-(2-Chlorophenyl)ethyl)piperazin-1-yl)-4,5-
 dihydrobenzo[*q*]indazole

 Oxalate salt, pale yellow hexagonal plates,
m.p. 134-136°C (from ethanol) (Found; C, 61.58; H, 5.61;
N, 11.33. C₂₃H₂₅N₄Cl·(COOH)₂·0.2 H₂O requires C, 61.71;
10 H, 5.68; N, 11.51%); δH (360 MHz, d₆-DMSO), 2.66 (2H, t,
J=8.0Hz, CH₂), 2.88 (2H, t, J=8.0Hz, CH₂), 3.03-3.07 (8H,
m, CH₂), 3.27 (4H, br s, CH₂), 7.19-7.47 (7H, m, ArH),
7.55 (1H, d, J=6.5, ArH) m/z (CI⁺, NH₃) 393 (M⁺+H).

15

EXAMPLE 22

3-(4-(1,2,3,4-Tetrahydronaphthyl-2-yl)piperazin-1-yl)-4,5-
 dihydro-1H-benzo[*q*]indazole

20 Oxalate salt, pale pink crystals, m.p. 208-
210°C (from ethanol) (Found; C, 61.39; H, 5.72; N, 10.26.
C₂₅H₂₈N₄·2(COOH)₂ requires C, 61.69; H, 5.71; N, 9.92%);
δH (360 MHz, d₆-DMSO), 1.78-1.80 (1H, m, CH_AH_B), 2.31
(1H, br s, CH_AH_B), 2.67 (2H, t, J=7.2Hz, CH₂), 2.83-3.07
25 (5H, m, CH₂), 3.17-3.20 (1H, m, CH), 3.39-3.57 (9H, m,
CH₂), 7.15-7.30 (7H, m, ArH), 7.56 (1H, d, J=7.2Hz, ArH)
m/z (CI⁺, NH₃) 385 (M⁺+H).

EXAMPLE 234-(4-Benzylpiperazin-1-yl)-5H-indeno[1,2-d]pyrimidin-2-ylamine

5

To dry isopropyl alcohol (10ml) was added sodium metal (154mg, 6.7mmol) and the mixture refluxed under N₂ until all of the sodium had dissolved (= 0.5h). To this solution was then added guanidine hydrochloride (64.3ml, 6.7mmol) and the suspension

10

refluxed for a further 0.5h. Meanwhile, 2-(methylthio[4-(*tert*-butyloxycarbonyl)-1-piperazinyl)methylene-indan-1-one (500mg, 1.34mmol) was dissolved in isopropylalcohol (3ml) and after 0.5h was added, in solution, to the refluxing suspension. The reaction was refluxed for 4h and then stirred at room temperature for 16h.

15

Work-up of the reaction was performed by pouring the mixture into saturated sodium bicarbonate solution (150ml) and extracting the products into ethyl acetate (2 x 50ml). The organic layer was then separated and washed with water and brine before being dried over Na₂SO₄ and concentrated *in vacuo*. The residues were

20

chromatographed upon flash silica eluting with dichloromethane:methanol (95:5 v/v) to give a pale yellow foam, δ (250MHz, CDCl₃) 1.50 (9H, s, C(CH₃)₃), 3.52-3.58 (4H, m, NCH₂), 3.80-3.86 (4H, m, NCH₂), 3.90 (2H, s, ArCH₂), 4.8 (2H, br s, NH₂), 7.44-7.48 (2H, m, ArH), 7.55-7.58 (1H, m, ArH), 7.98-8.02 (1H, m, ArH). This was deprotected with trifluoroacetic acid and then N-benzylated with benzyl bromide to give the title compound as pale yellow crystals, mp 175-180°C (from ethanol) (Found: C, 70.74; H, 6.28; N, 18.46. C₂₂H₂₃N₅·0.8H₂O requires C, 71.06; H, 6.67; N, 18.83%) δ (360MHz, 353K, d₆-DMSO) 2.53 (4H, m, NCH₂CH₂), 3.56 (2H, s, ArCH₂C), 3.80 (4H, NCH₂CH₂), 3.93 (2H, s, ArCH₂N), 5.8 (2H, br s, NH₂), 7.25-7.44 (7H, m, ArH), 7.55 (1H, d, *J* = 6.7Hz, ArH), 7.78 (1H, d, *J* = 7.6Hz, ArH) *m/z* (CI⁺, NH₃) 358 (*M*⁺+H).

30

EXAMPLE 24

5 4-(4-(2-Phenylethyl)piperazin-1-yl)-5H-indeno[1,2-d]pyrimidin-
 2-ylamine

10 Pale yellow crystals, mp 122-124°C (from ethanol) (Found: C, 73.57; H, 6.60; N, 18.49. $C_{23}H_{25}N_5 \cdot 0.8H_2O$ requires C, 73.65; H, 6.82; N, 18.67%) δ_H (360MHz, d_6 -DMSO) 2.51-2.59 (6H, m, $ArCH_2CH_2$ and NCH_2CH_2), 2.76-2.80 (2H, m, $ArCH_2CH_2N$), 3.76-3.79 (4H, m, NCH_2CH_2), 3.96 (3H, s, $ArCH_2C$), 6.04 (2H, br s, NH_2), 7.16-7.31 (5H, m, ArH), 7.38-7.46 (2H, m, ArH), 7.57 (1H, d, $J = 6.5Hz$, ArH), 7.75 (1H, dd, $J = 6.6Hz$ and $2.1Hz$, ArH) m/z (CI^+ , NH_3) 327 ($M^+ + H$).


15

- 40 -

CLAIMS:

1. A compound of formula I, or a salt thereof or a prodrug thereof:

5



wherein the broken line represents a double bond whereby the heteroaromatic ring containing Q is aromatic;

W represents the residue of an optionally substituted aromatic or heteroaromatic ring;

20 Q represents the residue of a heteroaromatic ring selected from =N-NR⁵-, -NR⁵-N=, =N-O-, -O-N= and =N-CR⁶=N-;

Z represents a chemical bond, an oxygen or sulphur atom, or a methylene or ethylene group;

25 R¹, R² and R⁵ independently represent hydrogen or C₁₋₆ alkyl;


one of R³ and R⁴ represents hydrocarbon or a heterocyclic group, and the other of R³ and R⁴ represents hydrogen, hydrocarbon or a heterocyclic group; and

30 R⁶ represents C₁₋₆alkyl or -NR^aR^b, in which R^a and R^b independently represent hydrogen or C₁₋₆alkyl.

2. A compound as claimed in claim 1 represented by formula (IA), and salts and prodrugs thereof:

35

- 41 -



wherein the broken circle represents two non-adjacent double bonds whereby the five-membered ring containing X and Y is aromatic;

15

W represents the residue of an optionally substituted aromatic or heteroaromatic ring;

one of X and Y represents nitrogen, and the other of X and Y represents oxygen or N-R⁵;

20

Z represents a chemical bond, an oxygen or sulphur atom, or a methylene or ethylene group;

R¹, R² and R⁵ independently represent hydrogen or C₁₋₆ alkyl; and

25


one of R³ and R⁴ represents hydrocarbon or a heterocyclic group, and the other of R³ and R⁴ represents hydrogen, hydrocarbon or a heterocyclic group.

3. A compounds as claimed in claim 1 represented by formula (IB), and salts and prodrugs thereof:

30

35

- 42 -



(1B)

wherein

W represents the residue of an optionally substituted aromatic or heteroaromatic ring;

15 Z represents a chemical bond, an oxygen or sulphur atom, or a methylene or ethylene group;

R¹ and R² independently represent hydrogen or C₁₋₆ alkyl;

20 one of R³ and R⁴ represents hydrocarbon or a heterocyclic group, and the other of R³ and R⁴ represents hydrogen, hydrocarbon or a heterocyclic group; and


R⁶ represents C₁₋₆ alkyl or -NR^aR^b, in which R^a and R^b independently represent hydrogen or C₁₋₆ alkyl.

25 4. A compound as claimed in claim 1 represented by formula IIA, and salts and prodrugs thereof:

30

35

- 43 -



(IIA)

wherein

Z is as defined in claim 1;

Y¹ represents oxygen or N-R¹⁵;

R¹³ represents C₂₋₆ alkenyl, C₃₋₇
 15 cycloalkyl(C₁₋₆)alkyl, aryl(C₁₋₆)alkyl or
 heteroaryl(C₁₋₆)alkyl, any of which groups may be
 optionally substituted;

R¹⁵ represents hydrogen or C₁₋₆ alkyl; and


R¹⁶ represents hydrogen, halogen,
 20 trifluoromethyl, cyano, nitro, amino, C₁₋₆ alkylamino,
 di(C₁₋₆)alkylamino, C₁₋₆ alkyl, C₁₋₆ alkoxy,
 aryl(C₁₋₆)alkoxy or C₂₋₆ alkylcarbonyl.

5. A compound as claimed in claim 1
 25 represented by formula IIB, and salts and prodrugs
 thereof:

30

35

- 44 -




(IIB)

wherein

- 15 X^1 represents oxygen or $N-R^{15}$;
 Z is as defined in claim 1; and
 R^{13} , R^{15} and R^{16} are as defined in claim 4.

6. A compound as claimed in claim 1
 represented by formula IIC, and salts and prodrugs
 thereof:

20




(IIC)

wherein

- 30 Z is as defined in claim 1;
 R^{13} and R^{16} are as defined in claim 4; and
 X^1 is as defined in claim 5.

35 7. A compound as claimed in claim 1
 represented by formula IID, and salts and prodrugs
 thereof:

- 45 -



(IID)

wherein


Z is as defined in claim 1;

R¹³ represents C₂₋₆ alkenyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl, aryl(C₁₋₆)alkyl or
 15 heteroaryl(C₁₋₆)alkyl, any of which groups may be optionally substituted;

R¹⁴ represents C₁₋₆ alkyl, amino, C₁₋₆ alkylamino or di(C₁₋₆)alkylamino; and

R¹⁶ represents hydrogen, halogen,
 20 trifluoromethyl, cyano, nitro, amino, C₁₋₆ alkylamino, di(C₁₋₆)alkylamino, C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl(C₁₋₆)alkoxy or C₂₋₆ alkylcarbonyl.

8. A compound as claimed in claim 1
 25 represented by formula IIE, and salts and prodrugs thereof:



(IIE)

- 46 -

wherein

Z is as defined in claim 1; and

R¹³, R¹⁴ and R¹⁶ are as defined in claim 7.

5 9. A compound selected from:

3-[4-(2-phenylethyl)piperazin-1-yl]-4,5-dihydro-1H-benzo[g]indazole;

3-(4-benzylpiperazin-1-yl)-4,5-dihydro-1H-benzo[g]indazole;

10 3-[4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)piperazin-1-yl]-4,5-dihydro-1H-benzo[g]indazole;

3-(4-benzylpiperazin-1-yl)-4,5-dihydronaphth[1,2-c]-isoxazole;

15 3-[4-(2-phenylethyl)piperazin-1-yl]-4,5-dihydronaphth[1,2-c]isoxazole;

3-[4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)piperazin-1-yl]-4,5-dihydronaphth[1,2-c]isoxazole;

3-[4-(2-phenylethyl)piperazin-1-yl]-4,5-dihydro-2-methyl-2H-benzo[g]indazole;

20 3-[4-(2-phenylethyl)piperazin-1-yl]-4,5-dihydro-1-methyl-1H-benzo[g]indazole;

3-[4-(2-phenylethyl)piperazin-1-yl]-4,5-dihydro-1H-thieno[2,3-g]indazole;

25 3-(4-benzylpiperazin-1-yl)-1,4-dihydroindeno[1,2-c]pyrazole;

3-[4-(2-phenylethyl)piperazin-1-yl]-1,4-dihydroindeno[1,2-c]pyrazole;

3-(4-benzylpiperazin-1-yl)-1-methyl-1,4-dihydroindeno[1,2-c]pyrazole;

30 3-[4-(2-phenylethyl)piperazin-1-yl]-1-methyl-1,4-dihydroindeno[1,2-c]pyrazole;

3-[4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)piperazin-1-yl]-1-methyl-1,4-dihydroindeno[1,2-c]pyrazole;

35 4-(4-benzylpiperazin-1-yl)-5H-indeno[1,2-d]pyrimidin-2-ylamine;

- 47 -

4-[4-(2-phenylethyl)piperazin-1-yl]-5H-indeno[1,2-d]pyrimidin-2-ylamine;
and salts and prodrugs thereof.

5 10. A pharmaceutical composition comprising a compound as claimed in any one of the preceding claims in association with a pharmaceutically acceptable carrier.

10 11. A compound as claimed in any one of claims 1 to 9 for use in therapy.

15 12. The use of a compound as claimed in any one of claims 1 to 9 for the manufacture of a medicament for the treatment and/or prevention of disorders of the dopamine system.



20 13. A method for the treatment and/or prevention of disorders of the dopamine system, which method comprises administering to a patient in need of such treatment an effective amount of a compound as claimed in any one of claims 1 to 9.

25 14. A process for the preparation of a compound as claimed in claim 1, wherein Q represents =N-NR⁵-, -NR⁵-N=, =N-O- or -O-N=, which comprises reacting a compound of formula III with a compound of formula IVa:

30

35



- 48 -



(IVa)

wherein W, Z, R^1 , R^2 and R^4 are as defined in claim 1, R^{30} corresponds to the group R^3 as defined in claim 1 or represents an amino-protecting group, X^a represents oxygen or $\text{N}-\text{R}^5$ in which R^5 is as defined in claim 1, and L^1 represents a suitable leaving group; followed, where necessary, by removal of the amino-protecting group R^{30} ; and followed, if necessary, by separation of the resulting mixture of isomers; and subsequently, if desired, converting a compound of formula I initially obtained into a further compound of formula I by conventional methods.

15. A process for the preparation of a compound as claimed in claim 1, wherein Q represents $=\text{N}-\text{CR}^6=\text{N}-$, which comprises reacting a compound of formula III with a compound of formula IVb:



(IVb)

- 49 -

wherein W, Z, R¹, R², R⁴ and R⁶ are as defined in claim 1, R³⁰ corresponds to the group R³ as defined claim 1 or represents an amino-protecting group, and L¹ represents a suitable leaving group; in the presence of a base;

5 followed, where necessary, by removal of the amino-protecting group R³⁰; and subsequently, if desired, converting a compound of formula I initially obtained into a further compound of formula I by conventional methods.

10

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/GB 94/01936

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D231/54 C07D261/20 C07D239/70 C07D471/04 C07D495/04
 C07D405/12 A61K31/42 A61K31/415 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 384 228 (DAINIPPON PHARMACEUTICAL CO., LTD.) 29 August 1990 see the whole document ---	1-15
X,P	WO,A,94 10162 (MERCK SHARP & DOHME LIMITED) 11 May 1994 see the whole document ---	1-15
A	EP,A,0 494 817 (ADIR ET COMPAGNIE) 15 July 1992 see the whole document ---	1-15
A	EP,A,0 402 644 (HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED) 19 December 1990 see claims; examples -----	1-15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

20 December 1994

Date of mailing of the international search report

- 4. 01. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+ 31-70) 340-3016

Authorized officer

Bosma, P

INTERNATIONAL SEARCH REPORT

Int'l Application No.

PCT/GB94/01936

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 13 is directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Inter. Application No
PCT/US 94/01936

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
EP-A-0384228	29-08-90	AU-B-	622976	30-04-92
		AU-A-	4912290	30-08-90
		EP-A-	0484988	13-05-92
		JP-A-	2289551	29-11-90
		US-A-	5041443	20-08-91
		US-A-	5185338	09-02-93

WO-A-9410162	11-05-94	AU-B-	5341394	24-05-94

EP-A-0494817	15-07-92	FR-A-	2671350	10-07-92
		AU-B-	642570	21-10-93
		AU-A-	1006592	16-07-92
		CA-A-	2058878	09-07-92
		JP-A-	4308584	30-10-92
		US-A-	5173490	22-12-92

EP-A-0402644	19-12-90	AU-B-	640653	02-09-93
		AU-A-	5577090	22-11-90
		CA-A-	2017193	19-11-90
		CN-A-	1048037	26-12-90
		IL-A-	94425	27-02-94
		JP-A-	3063263	19-03-91
		JP-B-	6062580	17-08-94
		PL-B-	163965	31-05-94
		US-A-	5364866	15-11-94
